OncoSec Medical Inc ONCS Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Feb 18, 2021 (filed on Feb 23, 2021)

Insider Name:

Alpha Holdings, Inc.

Ownership Type:

Direct Ownership

Securities:

Warrants to Purchase Common Stock

Nature of Transaction:

X - in- or at-the-money exercise

# or value acquired/disposed of:

368,250

Price:

$0.01
Feb 18, 2021 (filed on Feb 23, 2021)

Insider Name:

Alpha Holdings, Inc.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

X - in- or at-the-money exercise

# or value acquired/disposed of:

368,250

Price:

$3.45
Feb 02, 2021 (filed on Feb 17, 2021)

Insider Name:

Leuthner Brian A

Ownership Type:

Direct Ownership

Securities:

Stock Option(Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

150,000

Price:

--
Feb 01, 2021 (filed on Feb 03, 2021)

Insider Name:

DelAversano Robert J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,750

Price:

--
Feb 01, 2021 (filed on Feb 02, 2021)

Insider Name:

O'Connor Daniel J.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,413

Price:

$7.71
Jan 25, 2021 (filed on Jan 27, 2021)

Insider Name:

China Grand Pharmaceutical & Healthcare Holdings Ltd

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

677,839

Price:

$5.45
Jan 25, 2021 (filed on Jan 27, 2021)

Insider Name:

China Grand Pharmaceutical & Healthcare Holdings Ltd

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

3,389,198

Price:

$5.45
Nov 20, 2020 (filed on Nov 23, 2020)

Insider Name:

Alpha Holdings, Inc.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-80,000

Price:

$4.92
Nov 19, 2020 (filed on Nov 20, 2020)

Insider Name:

Alpha Holdings, Inc.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-50,000

Price:

$5.10
Nov 18, 2020 (filed on Nov 19, 2020)

Insider Name:

Alpha Holdings, Inc.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,999

Price:

$5.24

Filings by filing date

Feb 18, 2021 (filed on Feb 23, 2021)

Insider Name:

Alpha Holdings, Inc.

Ownership Type:

Direct Ownership

Securities:

Warrants to Purchase Common Stock

Nature of Transaction:

X - in- or at-the-money exercise

# or value acquired/disposed of:

368,250

Price:

$0.01
Feb 18, 2021 (filed on Feb 23, 2021)

Insider Name:

Alpha Holdings, Inc.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

X - in- or at-the-money exercise

# or value acquired/disposed of:

368,250

Price:

$3.45
Feb 02, 2021 (filed on Feb 17, 2021)

Insider Name:

Leuthner Brian A

Ownership Type:

Direct Ownership

Securities:

Stock Option(Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

150,000

Price:

--
Feb 01, 2021 (filed on Feb 03, 2021)

Insider Name:

DelAversano Robert J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,750

Price:

--
Feb 01, 2021 (filed on Feb 02, 2021)

Insider Name:

O'Connor Daniel J.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,413

Price:

$7.71
Jan 25, 2021 (filed on Jan 27, 2021)

Insider Name:

China Grand Pharmaceutical & Healthcare Holdings Ltd

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

677,839

Price:

$5.45
Jan 25, 2021 (filed on Jan 27, 2021)

Insider Name:

China Grand Pharmaceutical & Healthcare Holdings Ltd

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

3,389,198

Price:

$5.45
Nov 20, 2020 (filed on Nov 23, 2020)

Insider Name:

Alpha Holdings, Inc.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-80,000

Price:

$4.92
Nov 19, 2020 (filed on Nov 20, 2020)

Insider Name:

Alpha Holdings, Inc.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-50,000

Price:

$5.10
Nov 18, 2020 (filed on Nov 19, 2020)

Insider Name:

Alpha Holdings, Inc.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,999

Price:

$5.24

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	24 N Main St PENNINGTON NJ 08534-2218
Tel:	N/A
Website:	oncosec.com
IR:	See website

Key People

Margaret Dalesandro Independent Chairman of the Board	Daniel J. O'Connor President, Chief Executive Officer, Director	Brian A. Leuthner Chief Operating Officer
Robert J. DelAversano Principal Accounting Officer, Controller	Joe Smith Vice President - Business Development

Business Overview

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's core platform technology, ImmunoPulse, is a drug-device therapeutic modality comprised of intratumoral electroporation (EP) delivery device. The ImmunoPulse platform is designed to deliver plasmid deoxyribonucleic acid (DNA)-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The ImmunoPulse device can be adapted to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. The Company's lead product candidate is a DNA-encoded interleukin-12 (IL-12) called tavokinogene telseplasmid (TAVO).

Financial Overview

For the three months ended 31 October 2020, OncoSecMedical Inc revenues was not reported. Net loss increased35% to $13.2M. Higher net loss reflects Research anddevelopment - Balancing val increase of 65% to $8.8M(expense), Stock-based Compensation in R&D increase from$100K to $1M (expense), Stock-based Compensation in SGAincrease from $300K to $900K (expense).

Employees:	42 as of Jul 31, 2020

Reporting Currency:	U.S. Dollars
Enterprise value:	$162.48M as of Oct 31, 2020
Annual revenue (TTM):	$0.00M as of Oct 31, 2020
EBITDA (TTM):	-$46.34M as of Oct 31, 2020
Net annual income (TTM):	-$45.72M as of Oct 31, 2020
Free cash flow (TTM):	-$34.75M as of Oct 31, 2020
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	35,405,888 as of Jan 21, 2021
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

OncoSec Medical Inc (OQ:ONCS)